Tempest Therapeutics (TPST)’ PPARalpha inhibitor, a treatment of hepatocellular carcinoma, received FDA orphan designation, according to a post on the agency’s site.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPST:
- Tempest Therapeutics Reports Q3 2024 Financial Results
- Tempest Therapeutics price target lowered to $5 from $8 at Piper Sandler
- Tempest Therapeutics reports Q3 EPS (41c), consensus (36c)
- Tempest receives FDA study may proceed for Phase 3 trial of amezalpat
- Tempest Therpeutics options imply 22.5% move in share price post-earnings